Authors : Sarika Saini; Dr. Rekha Tara Singh Rajput

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/bdrp3ke4

Scribd : https://tinyurl.com/4rnhurwa

DOI : https://doi.org/10.38124/ijisrt/26May1789

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Depression remains one of the most prevalent neuropsychiatric disorders globally and significantly contributes to disability, reduced quality of life, and socioeconomic burden. Conventional antidepressant therapies are associated with several limitations including delayed onset of action, poor patient compliance, inadequate blood–brain barrier penetration, and systemic adverse effects. Recent pharmaceutical advancements have focused on nanotechnology-based drug delivery systems, bilayer tablets, controlled-release formulations, and chronotherapeutic approaches to improve antidepressant efficacy and safety. The present review comprehensively discusses recent progress in bilayer tablet systems, nanoformulations, intranasal antidepressant delivery, melatonin-assisted therapy, neuroinflammation-targeted treatment, and brain-targeted drug delivery technologies. The review further highlights emerging molecular pathways involved in depression and discusses future perspectives associated with personalized and translational antidepressant therapy.

References :

1. Brzezinski, A. (2021) ‘Melatonin in sleep disorders: updated review’, Sleep Medicine Reviews, 55, pp. 101–108.
2. Ismail, A. et al. (2022) ‘Development of a novel bilosomal system for improved oral bioavailability of sertraline hydrochloride’, AAPS PharmSciTech, 23, p. 188.
3. Patel, R.B. et al. (2022) ‘Comprehending the potential of metallic, lipid, and polymer-based nanocarriers for treatment and management of depression’, Neurochemical International, 153, p. 105259.
4. Yuan, S. et al. (2023) ‘Novel drug delivery strategies for antidepressant active ingredients from medicinal plants’, Journal of Nanobiotechnology, 21, p. 391.
5. Fu, S. et al. (2024) ‘ROS-targeted depression therapy via BSA-incubated ceria nanoclusters’, Nano Letters, 22(11), pp. 4519–4527.
6. Mohammed, H.S. et al. (2025) ‘Assessment of the therapeutic potential of hesperidin and quercetin nanoparticles’, Neurochemical Research.
7. Qiang, L. and Huo, Y. (2025) ‘Research progress of functionalized drug delivery nanosystems in regulating depression’, Pharmaceuticals, 18(12), p. 1858.
8. Zeng, J.W. et al. (2025) ‘Investigating the mechanisms of Sini San via BDNF/TrkB/PI3K/AKT pathway’, Frontiers in Psychiatry, 16, p. 1628634.
9. Zhang, S.Q. et al. (2025) ‘Costunolide normalizes neuroinflammation in depression’, Acta Pharmacologica Sinica, 46, pp. 1864–1876.
10. El-Dakroury, W.A. et al. (2026) ‘Evaluation of duloxetine-loaded nanoformulations for antidepressant activity’, International Journal of Nanomedicine.
11. Zhu, T.T. et al. (2026) ‘Clinical innovations and future directions of nanoparticles in psychiatric disorders’, Molecular Psychiatry.